B+
Bull case
25%
Probability
Target price
$0.90
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
MBIO
Mustang BioBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The best bull read on the post-earnings setup is that MBIO has meaningfully reduced operating burn, exited a costly facility, ended Q1 with $16.3 million in cash, and still has a live clinical forward hook in a possible Q3 2026 MB-109 investigator-sponsored study. If management converts the leaner cost base into a longer runway without immediate heavy dilution, the stock could re-rate from distressed levels.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Fortress-related 2.5% financing share grants and annual 2.5% stock dividend mechanics create recurring dilution pressure.
Momentum
52
Value
57
Sentiment
68
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.50 · Bull $0.90 · Bear $0.25Analysis 2026-05-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $10.00
Why
Momentum52 · Δ7d -
Value57 · Δ7d -0.0
Sentiment68 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite.
Contradictions & invalidation
- • Fortress-related 2.5% financing share grants and annual 2.5% stock dividend mechanics create recurring dilution pressure.
- • MB-109 timing is still exploratory rather than fully committed, so clinical initiation could slip beyond Q3 2026.
- • The bear case is that the Q1 filing did not introduce a new revenue source, pivotal trial inflection, or broad commercialization path, while the stock remains sub-$1, subject to Nasdaq cure requirements, and constrained by baby-shelf rules.
Catalyst clock
2026-05-31
Post-Q1 2026 filing digestion centers on runway rather than revenue upside
Lead driver: Sentiment · See AI snapshot
Momentum
52
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+1.4
Sentiment
68
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 51.8 / Value 56.9 / Sentiment 67.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.50
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.25
Analysis reference price unavailable
Analysis 2026-05-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$4.5M
Beta
2.14
Shares Out
7.58M
P/E (TTM) · Derived
-1.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.90
Rev YoY
-100.0%
EPS YoY
-16.0%
Gross Margin
-
Op Margin
-
Net Debt
-$17.27M
Current Ratio
1.97
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data